| Purpose | (Clinical Focus: This value set focuses on testosterone medications delivered through the skin (transdermal) for use in masculinizing hormone therapy (MHT) for transgender men. It includes various formulations and dosages of transdermal testosterone products.),(Data Element Scope: This value set applies to the category of medications used in MHT. It specifically captures transdermal testosterone formulations, excluding other administration routes like injections or implants. Transdermal options can include gels, patches, and scrotal applications.),(Inclusion Criteria: The value set encompasses a variety of transdermal testosterone products:
Gels with different concentrations (1%, 1.62%) applied in varying amounts based on the prescribed dosage.
Patches delivering different doses of testosterone over a 24-hour period (0.083mg/hr, 0.104mg/hr, 0.167mg/hr, 0.208mg/hr, 0.25mg/hr).
Brand and generic names are included for informational purposes (e.g., Androgel, Testoderm, Fortesta).),(Exclusion Criteria: This value set excludes testosterone medications delivered through other routes, such as injections or implants.
It does not include medications other than testosterone that may be used in MHT regimens, such as finasteride.
It excludes any specific application devices or instructions associated with the transdermal products.) |
FHIR